#EULAR2025 Abstr#LB0007 Two’s Company, Three’s a Crowd! In 5 #SLE pts treated with CC312, a novel CD19/CD3/CD28 tri-specific ab in dose escalation showed rapid & B-cell depletion & all achieved SRI-4. No =>G2 CRS or ICANS. USP: off-the-shelf & overcome T-cell exhaustion @RheumNow https://t.co/6DZRj09JEQ

Low disease activity more difficult to achieve in vulnerable populations. All rheumatic diseases - #RA #PsA #AS initiating DMARDs takes longer in these population #EULAR2025 @RheumNow https://t.co/voIivshKRt

What do we know about disparities in #SLE - worse in women - worse in non white populations - have lower quality of care in vulnerable populations - have worse outcomes in vulnerable populations #EULAR2025 @rheumnow Diagnosis itself is difficult in communities with poor access https://t.co/pcUaJ0eK65

#Lupus is one of the biggest social discriminators 🔺️Higher prevalence in Women 🔺️Higher prevalence in Non-Whites 🔺️More catastrophic manifestations in low socioeconomic groups Disaster Medicine Session Social disparities and impact on outcomes #EULAR2025 @RheumNow https://t.co/mewR9NzXHt

Dual pandemic in Africa. Increasing lifestyle diseases and obesity, along with infections and malnutrition. These may be reflected in rheumatic diseases too (if they could be studied in detail) #EULAR2025 @RheumNow https://t.co/6ulMRxX8az

Targets for OA pain pharmacotherapies some by the wayside: - NGF - TrkA but some very much in play and exciting: - neurotrophin-3 - TRPV1 - Nav1.7, 1.8 Fiona Watt #EULAR2025 @RheumNow https://t.co/DXDKNnVRRo

In the APEX Phase 3b RCT (N=1020), guselkumab (IL-23p19 inhibitor) significantly reduced radiographic progression (ΔvdH-S 0.55 & 0.54 vs 1.35 PBO; p≤0.002) and improved ACR20 (67–68% vs 47%) at W24 in biologic-naïve PsA. Safety consistent with prior data. Abstract LB0010 https://t.co/mFDsBsCg6m

Migrant health literacy challenges - Individual interviews with participants with rheumatic diseases (interpreters used) multiple aspects - Individual, Providers and system level Navigating health care systems #EULAR2025 @RheumNow https://t.co/cWQ6jP8RZe

RCT in axSpA (N=200): Digital therapeutic Axia added to stable treatment led to significant improvements in BASDAI (–1.66), BASFI (–1.12), ASQoL (–2.51), with ASAS20/40 responses of 51%/23% vs 9%/3% for usual care. Supports role of DTx in axSpA care. Abstract LB0002 @RheumNow https://t.co/oF6bjIwNIY

LEVI-04 (neutrophin-3 inhibitor presented as #ACR24 late-breaker in knee OA) more good efficacy data, no rapidly progressive OA safety signal. For us clinicians: impressive impact size, esp relative to alternatives. Finally, something that works?? #EULAR2025 OP0374 @RheumNow https://t.co/iVdlwyaqrv